Table 3 Univariable analysis for AKI [27 of 228 (11.8 %) patients with AKI]

Treatment

 Vancomycin

4/101

(0.058, 0.544)

0.003*

 Piperacillin/tazobactam

4/26

(0.242, 2.545)

0.69

 Combination vanc + piptazo

19/101

 Vanc

(0.053, 0.978)

0.047*

 Piptazo

Age

 Per 1 year increase

(0.968, 1.021)

0.69

Sex

 Male

11/148

(0.141, 0.731)

0.007*

 Female

16/80

Race

 Caucasian

1/34

 African-American

26/182

(0.721–41.968)

0.10

BMI

 ≥30 kg/m²

9/43

(1.053, 6.760)

0.04*

 <30 kg/m²

13/144

Creatinine clearance

 <Median of 71.94 ml/min

11/95

(0.396, 2.347)

0.94

 ≥Median of 71.94 ml/min

11/92

 Per 10 ml/min decrease

(0.922, 1.192)

0.47

Nephrotoxic agents

 IV contrast, yes

8/50

(0.652, 3.894)

0.31

 IV contrast, no

19/178

 Aminoglycoside, yes

1/8

(0.126, 9.014)

0.95

 Aminoglycoside, no

26/220

 NSAIDs, yes

5/31

(0.530, 4.368)

0.44

 NSAIDs, no

22/196

 Tenofovir, yes

2/13

(0.290, 6.599)

0.68

 Tenofovir, no

25/215

 ≥2 agents

1/17

(0.057, 3.495)

0.44

 <2 agents

26/211

Diabetes

 Yes

7/49

(0.525, 3.343)

0.55

 No

20/179

Hypertension

 Yes

14/91

(0.774, 3.886)

0.18

 No

13/137

Malignancy

 Yes

3/16

(0.480, 6.803)

0.38

 No

24/212

CKD

 Yes

2/12

(0.317, 7.377)

0.60

 No

25/216

HIV

 Yes

6/50

(0.388, 2.681)

0.97

 No

21/178